Allogene Therapeutics Inc (ALLO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) has a cash flow conversion efficiency ratio of -0.094x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.69 Million) by net assets ($315.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Allogene Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Allogene Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Allogene Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ALLO total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Allogene Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allogene Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Kylinsec Technology Co. Ltd. A
SHG:688152
|
N/A |
|
Shanghai Xujiahui Commercial Co Ltd
SHE:002561
|
0.021x |
|
Dongwon System
KO:014820
|
0.072x |
|
LF Corp
KO:093050
|
0.051x |
|
Lets Holding Group Co Ltd
SHE:002398
|
0.022x |
|
Paslin Digital Technology Co Ltd
SHG:600215
|
0.030x |
|
Beijing Kaiwen Education Technology Co Ltd
SHE:002659
|
0.034x |
|
MMTEC Inc
NASDAQ:MTC
|
-0.138x |
Annual Cash Flow Conversion Efficiency for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Allogene Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Allogene Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $422.18 Million | $-200.30 Million | -0.474x | -2.23% |
| 2023-12-31 | $512.23 Million | $-237.73 Million | -0.464x | -40.35% |
| 2022-12-31 | $666.88 Million | $-220.52 Million | -0.331x | -65.54% |
| 2021-12-31 | $925.20 Million | $-184.81 Million | -0.200x | -87.38% |
| 2020-12-31 | $1.08 Billion | $-115.09 Million | -0.107x | +51.18% |
| 2019-12-31 | $629.02 Million | $-137.35 Million | -0.218x | -243.85% |
| 2018-12-31 | $703.16 Million | $-44.65 Million | -0.064x | -100.00% |
| 2017-12-31 | $-2.00K | $-44.65 Million | 22326.500x | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more